Asia-Pacific Oncology Molecular Diagnostics Market to Reach $1.24 Bn, Globally, by 2031 at 7.3% CAGR: AMR

Government initiatives promoting healthcare infrastructure development and growing investments in research further support market growth.

PORTLAND, OR, UNITED STATES, July 10, 2025 /EINPresswire.com/ -- Allied Market Research published a report, titled, "Asia–Pacific Oncology Molecular Diagnostics Market, was estimated at 610.17 million in 2021, and is expected to hit $1.24 billion by 2031, registering a CAGR of 7.3% from 2022 to 2031. The Asia-Pacific oncology molecular diagnostics market is driven by rising cancer prevalence, increasing awareness about early diagnosis, and advancements in molecular diagnostic technologies.

Download Sample PDF at:
https://www.alliedmarketresearch.com/request-sample/6652

Key Factors Shaping the Asia-Pacific Oncology Molecular Diagnostics Market

The Asia-Pacific oncology molecular diagnostics market is witnessing significant growth, fueled by several influential factors. The increasing prevalence of various cancer types, an aging population, and advancements in biomarker identification and molecular diagnostics technologies are driving market expansion. Additionally, evolving lifestyles and rising demand for precision medicine contribute to this upward trend. However, the market still faces challenges such as limited healthcare coverage and low public awareness about the importance of specialized diagnostic tools and skilled professionals. Despite these hurdles, growing government initiatives aimed at cancer awareness and early detection are expected to unlock new growth opportunities in the region.

Impact of COVID-19

During the COVID-19 pandemic, the market experienced a setback due to a sharp decline in cancer-related consultations and screenings. Many patients delayed or avoided visits to clinics and hospitals, affecting the overall diagnostic rate. However, with improved healthcare access and post-pandemic recovery efforts, the market has rebounded and is on course to regain momentum.

Lung Cancer Segment Leading the Way

Among applications, the lung cancer segment dominated the market in 2021, accounting for roughly one-fourth of the total share. It is also anticipated to be the fastest-growing segment, with a projected CAGR of 7.9% during the forecast period. This growth is primarily attributed to increased aging populations, lifestyle changes, and improvements in early cancer detection methods, particularly through biomarkers.

Specific Requirement on COVID-19? Ask to Our Industry Expert:
https://www.alliedmarketresearch.com/purchase-enquiry/6652

The PCR segment to dominate by 2031-

By application, the PCR segment contributed to the lion's share in 2021, holding more than one-third of the Asia-Pacific oncology molecular diagnostics market. Increase in adoption of polymerase chain reaction (PCR) as it offers various advantages such as less time-consuming process drives the segment growth. However, the NGS segment is expected to manifest the fastest CAGR of 8.0% from 2022 to 2031. This is because it is easy to handle and requires low concentration of sample for test.

Rest of Asia-Pacific held the major share in 2021-

By region, the market across Rest of Asia-Pacific dominated in 2021, garnering more than four-fifths of the Asia-Pacific oncology molecular diagnostics market. The same region is also expected to cite the fastest CAGR of 7.7% throughout the forecast period. This is due to increase in adoption and acceptance for personalized medicines, up gradation of healthcare infrastructure, and higher investments for R&D activities across the province. The other countries analyzed in the report include Australia, Vietnam, Indonesia, Thailand, Philippines, Malaysia, and Singapore.

Key players in the industry-

• BioMerieux
• Amoy Dx
• Sysmex Corporation
• F.Hoffmann-LA Roche Ltd.
• Siemens Healthcares
• Danaher Corporation
• Thermo Fisher
• Agilent Technologies Inc.
• Abbott Laboratories
• Diasorin SP

Frequently Asked Questions?

Q1. Which is base year calculated in the Asia–Pacific oncology molecular diagnostics market report?

Q2. Which are the top companies holding the market share in Asia–Pacific oncology molecular diagnostics market?

Q3. Which is the most influencing segment growing in the Asia–Pacific oncology molecular diagnostics market report?

Q4. What factors drive the growth of Asia–Pacific oncology molecular diagnostics market?

Q5. What is Oncology Molecular Diagnostic Testing?

About Us -

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa
Allied Market Research
+ +1 800-792-5285
email us here
Visit us on social media:
LinkedIn
Facebook
YouTube
X